AU6113896A - Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production - Google Patents

Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production

Info

Publication number
AU6113896A
AU6113896A AU61138/96A AU6113896A AU6113896A AU 6113896 A AU6113896 A AU 6113896A AU 61138/96 A AU61138/96 A AU 61138/96A AU 6113896 A AU6113896 A AU 6113896A AU 6113896 A AU6113896 A AU 6113896A
Authority
AU
Australia
Prior art keywords
suppress
th1
use
antibody production
oral tolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61138/96A
Inventor
Youhai Chen
Aharon Friedman
Howard L. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University
Brigham and Women's Hospital
Original Assignee
Yissum Research Development Co of Hebrew University
Brigham and Women's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US46559295A priority Critical
Application filed by Yissum Research Development Co of Hebrew University, Brigham and Women's Hospital filed Critical Yissum Research Development Co of Hebrew University
Priority to PCT/US1996/010386 priority patent/WO1996039176A1/en
Publication of AU6113896A publication Critical patent/AU6113896A/en
Priority to US465592 priority
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
AU61138/96A 1995-06-05 1996-06-05 Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production Abandoned AU6113896A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US46559295A true 1995-06-05 1995-06-05
PCT/US1996/010386 WO1996039176A1 (en) 1995-06-05 1996-06-05 USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
US465592 1999-12-17

Publications (1)

Publication Number Publication Date
AU6113896A true AU6113896A (en) 1996-12-24

Family

ID=23848397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61138/96A Abandoned AU6113896A (en) 1995-06-05 1996-06-05 Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production

Country Status (2)

Country Link
AU (1) AU6113896A (en)
WO (1) WO1996039176A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US6022697A (en) * 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
AT306931T (en) * 1997-12-03 2005-11-15 Neuralab Ltd Suppression of changes in connection with beta-amyloid in Alzheimer's
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2002088304A2 (en) * 2001-04-11 2002-11-07 Trustees Of The University Of Pennsylvania Compositions and methods for suppressing immune responses
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (en) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanized anti-beta
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9007527A (en) * 1989-07-14 1992-06-23 Autoimmune Inc Method to treat or prevent the clinical manifestation of a disease having the symptoms of uveoretinitis and pharmaceutical formulation for treating mammals suffering from uveoretinitis
CA2129351A1 (en) * 1992-02-10 1993-08-19 Barton F. Haynes Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens

Also Published As

Publication number Publication date
WO1996039176A1 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
AU665206B2 (en) Preparation of microparticles
DE3467093D1 (en) Marine organism extracts and their preparation
AU652928B2 (en) Lipid-selective antioxidants and their preparation and use
AU652601B2 (en) Dental model and process of making same
AU645379B2 (en) Sanitary napkin having components capable of separation in use
AU689697B2 (en) Process for the production of modified aerogels and use thereof
AU691980B2 (en) Expression and export technology of proteins as immunofusins
EP1162272B8 (en) Generation of immune responses to prostate-specific antigen (PSA)
AU659417B2 (en) Processing of yeast refuse and resulting product
AU591774B2 (en) Lysine salt of the gadolinium-dota complex and its applications to diagnosis
NZ237483A (en) Preparation of uniformly sized particles in the range of 1 to 50#m#m
IL129319A (en) Polycyclic imidazopyridinamine immune response modifiers for treatment of th2 mediated and related diseases
AU628959B2 (en) Aluminum-base oxides, moldings thereof, and production of said oxides
AU5569896A (en) Novel synthesis and use of beta-lapachone analogs
ZA9505832B (en) Reshaped human antibody to human interleukin-8
AU3836695A (en) In vitro induction of dopaminergic cells
AU659622B2 (en) Efficient microcapsule preparation and method of use
AU1158297A (en) Production of gad65 in methylotrophic yeast
AU2326892A (en) Acylmercaptoalkanoyldipeptides, methods of preparation and their therapeutic use
AU626082B2 (en) Preparation of stearidonic acid
AU2361995A (en) Compositions comprising fused particulates and methods of making them
AU8639291A (en) Printable coplanar laminates and method of making same
AU8565691A (en) Perfumed underarm hygiene products
AU5771090A (en) Ultra mild skin cleansing composition
AU1157697A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof